Identification of a Proteomic Signature for Predicting Immunotherapy Response in Patients With Metastatic Non-Small Cell Lung Cancer.

Mol Cell Proteomics · 2024 · PMC11474190 · PMID 39216661

Europe PMC DOI

hedged sentence

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

showed a trendp = 0.054so close (0.05 < p ≤ 0.1)

Additionally, low levels of HPS5 showed a trend towards being associated with longer PFS (log-rank p = 0.054) and were significantly associated with longer OS (log-rank p < 0.001).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.